uniQure (QURE) Expected to Announce Earnings on Tuesday

uniQure (NASDAQ:QURE) will likely be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter.

uniQure Stock Up 1.1 %

Shares of QURE opened at $14.12 on Tuesday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The stock’s 50-day moving average price is $11.95 and its 200-day moving average price is $11.68. The company has a market capitalization of $763.57 million, a price-to-earnings ratio of -2.87 and a beta of 0.42.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Wells Fargo & Company dropped their target price on uniQure from $35.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Friday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. Chardan Capital assumed coverage on uniQure in a research report on Tuesday, April 1st. They issued a “buy” rating and a $38.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $70.00 target price on shares of uniQure in a research note on Monday, April 21st. Finally, StockNews.com raised shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.80.

Insider Transactions at uniQure

In other news, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the transaction, the chief executive officer now owns 651,454 shares in the company, valued at $6,703,461.66. The trade was a 4.17 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the sale, the chief financial officer now directly owns 155,168 shares of the company’s stock, valued at $1,756,501.76. This represents a 1.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 90,830 shares of company stock valued at $961,401. Corporate insiders own 4.74% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.